Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4665-4672

  Sundstrøm, Stein ^a   Bremnes, Roy M ^a   Kaasa, Stein ^a   Aasebø, Ulf ^a   Hatlevoll, Reidulv ^a   Dahle, Ragnar ^a   Boye, Nils ^a   Wang, Mari ^a   Vigander, Tor ^a   Vilsvik, Jan ^a   Skovlund, Eva ^a   Hannisdal, Einar ^a   Aamdal, Steinar ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; SKULL IRRADIATION; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION; SURVIVAL RATE; VINCRISTINE;

EID: 0037115426     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.111     Document Type: Article

References (39)

1. Souhami RL, Law K: Longevity in small cell lung cancer: A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 61:584-589, 1990
2. Lassen U, Østerlind K, Hansen M, et al: Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - An analysis of 1714 consecutive patients. J Clin Oncol 13:1215-1220, 1995
3. Watkin SW, Hayhurst GK, Green JA: Time trends in the outcome of lung cancer management: A study of 9090 cases diagnosed in the Mersey Region, 1974-86. Br J Cancer 61:590-596, 1990
4. Sandier AB: Current management of small cell lung cancer. Semin Oncol 24:463-476, 1997
5. Kelly K: New chemotherapy agents for small cell lung cancer. Chest 111:156S-162S, 2000 (suppl 1)
6. Seifter EJ, Ihde DC: Therapy of small cell lung cancer: A perspective on two decades of clinical research. Semin Oncol 15:278-299, 1988
7. Sierocki JS, Hilaris BS, Hopfan S, et al: cis-Dichlorodiammineplatihum (Il) and VP-16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63:1593-1597, 1979
8. Einhorn LH: Initial therapy with cisplatin plus VP-16 in small cell lung cancer. Semin Oncol 13:5-9, 1986 (suppl 3)
9. Hirsch F, Hansen HH, Hansen M, et al: The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: A randomized trial of 288 consecutive patients. J Clin Oncol 4:585-591, 1987
10. Evans WM, Shepard FA, Feld R, et al: VP-16 and cisplatin as first line-therapy for small cell lung cancer. J Clin Oncol 3:1471-1477, 1985
11. Einhorn LH, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small cell lung cancer. J Clin Oncol 6:451-456, 1988
12. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alteration of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
13. Roth BJ, Johnsen DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alteration of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
14. Wampler GL, Heim WJ, Ellison NM, et al: Comparison of cyclophosphamide, doxorubicin and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin and vincristine in the treatment of extensive-disease small-cell lung carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 9:1438-1445, 1991
15. Ettinger DS: Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. Semin Radiat Oncol 9:148-150, 1999 (suppl 1)
16. Johnson D: Management of small cell lung cancer: Current state of the art. Chest 116:525S-530S, 1999 (suppl)
17. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
18. Pignon JP, Arrigada R, Ihde D, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992
19. Warde P, Payne D: Does thoracic irradiation improve survival, and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895, 1992
20. Auperin A, Arrigada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341:476-484, 1999
21. Gregor A, Cull A, Stephens RJ, et al: Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Result of a multicentre randomised trial. Eur J Cancer 33:1752-1758, 1997
22. Work E, Bentzen SM, Nielsen OS, et al: Prophylactic cranial irradiation in limited stage small cell lung cancer: Survival benefit in patients with favorable characteristics. Eur J Cancer 32A:772-778, 1996
23. Aaronson NK, Ahmedzai S, Bergmam B, et al: The European Organization for Research and Treatment of Cancer QLQ-C-30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
24. Bergmann B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials - EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994
25. Kaasa S, Bjordal K, Aaronson N, et al: The EORTC core quality of life questionnaire (QLQ-C30): Validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 31A:2260-2263, 1995
26. Bergmann B, Sullivan S, Sørenson S: Quality of life during chemotherapy for small cell lung cancer: A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile. Acta Oncol 31:19-28, 1992
27. King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555-567, 1996
28. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
29. Boni C, Cocconi G, Bisagni G, et al: Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. Cancer 63:638-642, 1989
30. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107:451-458, 1987
31. Havemann K, Wolf M, Holle R, et al: Alternating versus sequential chemotherapy in small cell lung cancer: A randomized German multicenter trial. Cancer 15:1072-1082, 1987
32. Goodman GE, Crowley JJ, Blasko JC, et al: Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: A Southwest Oncology Group study. J Clin Oncol 8:39-47, 1990
33. Postmus PE, Scagliotti G, Groen HJ, et al: Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase III trial. Eur J Cancer 32A:1498-1503, 1996
34. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
35. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 4:679-688, 1988
36. Chute JP, Venzon DJ, Hankins L, et al: Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72:901-912, 1997
37. Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8-15, 2000
38. Mascaux C, Paesmans M, Berghmans T, et al: A systematic review of the role of etoposide and cisplatin in the chemotherapy in small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23-36, 2000
39. Turrisi AT, Kyungmann K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999